Autonomix CMO Robert Schwartz receives lifetime award

Woodlands, Texas - Autonomix Medical, Inc. has announced that its Chief Medical Officer, Robert Schwartz, will receive the prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award. The ceremony is set to take place on September 18, 2026, in Newport Beach, California. Awarded annually, this recognition acknowledges those who have significantly contributed to cardiovascular technology through scientific advancements, clinical innovations, and entrepreneurial leadership.

Schwartz boasts an impressive portfolio, with over 500 scientific publications to his name and more than 200 patents. He is the co-inventor of the Watchman device, which was subsequently acquired by Boston Scientific. As co-founder of Autonomix, Schwartz's career has been marked by an unwavering commitment to innovation, aiming to enhance the lives of patients worldwide.

According to Autonomix's President and CEO, Brad Hauser, Schwartz's receipt of this award is a testament to his relentless pursuit of innovation. Speaking on the occasion, Schwartz expressed his honor at receiving this recognition from the Cardiovascular Tech Forum, highlighting that innovation in medical technology is driven by collaboration among physicians, engineers, and entrepreneurs dedicated to improving patient outcomes.

Autonomix is a medical device company focused on developing catheter-based technology for diagnosing and treating diseases of the peripheral nervous system, with initial trials targeting pancreatic cancer. However, the technology has not yet secured clearance for marketing in the United States. The Cardiovascular Tech Forum is a platform that convenes physicians, engineers, entrepreneurs, and investors committed to advancing cardiovascular innovation. This report has been AI-generated and edited for accuracy.